Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.36 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22915965 | 0.81 | ACHE (0.50) | SIGMAR1DRD4DRD2DRD3KDM4E | |
| SCHEMBL22915892 | 0.79 | KMT2A (0.55) | TMEM97SIGMAR1DRD4HTR2BDRD2 | |
| SCHEMBL22915891 | 0.76 | CD44 (0.39) | DRD4KDM4EALDH1A1GLAGAA | |
| SCHEMBL20213794 | 0.76 | MEN1 (0.50) | SIGMAR1DRD4DRD2SMN1; SMN2 | |
| SCHEMBL20214655 | 0.75 | HSP90AB1 (0.44) | SIGMAR1KDM4EALDH1A1GLAGAA | |
| SCHEMBL20213815 | 0.74 | ALDH1A1 (0.51) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20213759 | 0.73 | CYP2D6 (0.49) | ADRA2AADRA2BDRD4HTR2BDRD2 | |
| SCHEMBL20214402 | 0.72 | REV1 (0.54) | KDM4EALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL550151 | 0.72 | SIGMAR1 (0.50) | SIGMAR1DRD4DRD2DRD3KDM4E | |
| SCHEMBL22915978 | 0.71 | HRH3 (0.47) | SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2021-11-30 | — | — | US | disclosed |
| EP-3548613-B1 | BACTERIAL GLUTAMINYL CYCLASE INHIBITORS AND USE THEREOF IN THE TREATMENT OF PERIODONTITIS | FRAUNHOFER GES FORSCHUNG (DE) | 2021-01-27 | — | — | EP | disclosed |
| EP-3548613-A1 | BACTERIAL GLUTAMINYL CYCLASES AND INHIBITORS THEREOF FOR USE IN THE TREATMENT OF PERIODONTITIS | Fraunhofer Gesellschaft zur Förderung der Angewand (DE) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018100159-A1 | BACTERIAL GLUTAMINYL CYCLASES AND INHIBITORS THEREOF FOR USE IN THE TREATMENT OF PERIODONTITIS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | GMPS, QPCT, GLS | L3MBTL3 4617/4885L3MBTL1 3855/4885MBTD1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.